Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group

International Journal of Hematology

Volumn 91, Issue 1, 2010, Pages 97-103

  Morita, Yasuyoshi ^a   Kanamaru, Akihisa ^a   Miyazaki, Yasushi ^b   Imanishi, Daisuke ^b   Yagasaki, Fumiharu ^c   Tanimoto, Mitsune ^d   Kuriyama, Kazutaka ^e   Kobayashi, Toru ^f   Imoto, Shion ^g   Ohnishi, Kazunori ^h   Naoe, Tomoki ⁱ   Ohno, Ryuzo ^j  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^c SAITAMA MEDICAL UNIVERSITY HOSPITAL   (Japan)

^d OKAYAMA UNIVERSITY   (Japan)

^e UNIVERSITY OF THE RYUKYUS   (Japan)

^f MIE UNIVERSITY   (Japan)

^g Japanese Red Cross Society   (Japan)

^h HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j AICHI CANCER CENTER HOSPITAL   (Japan)

more..

Author keywords

HSCT; Induction therapy; JALSG MDS200; MDS; MDS AML

Indexed keywords

ACLARUBICIN; CYTARABINE; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; HIGH RISK POPULATION; HUMAN; INFECTION; INTENSIVE CARE; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ACLARUBICIN; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; FEMALE; HUMANS; IDARUBICIN; JAPAN; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REMISSION INDUCTION; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 75049084540     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-009-0473-4     Document Type: Article

References (21)

1. P Mhawech 2001 Myelodysplastic syndrome: review of the cytogenetic and molecular data Crit Rev Oncol/Hematol 40 229 38 10.1016/S1040-8428(01)00101-9 1:STN:280:DC%2BD3MnptFCmtQ%3D%3D (Pubitemid 33111069)
2. W Hofmann HP Koeffler 2005 Myelodysplastic syndrome Ann Rev Med 56 1 16 10.1146/annurev.med.56.082103.104704 1:CAS:528:DC%2BD2MXisVSrsL0%3D 15660498 (Pubitemid 40299770)
3. JM Bennett D Catovsky MT Daniel G Flandrin DA Galton HR Gralnick, et al. 1982 Proposals for the classification of the myelodysplastic syndromes Br J Haematol 51 189 99 1:STN:280:DyaL383gs1GhtQ%3D%3D 6952920
4. J Finke A Nagler 2007 Viewpoint: what is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning-is there still an upper age limit? A focus on myeloid neoplasia Leukemia 21 1357 62 10.1038/sj.leu.2404741 1:CAS:528:DC%2BD2sXms1Wms7c%3D 17508002 (Pubitemid 46969869)
5. GJ Tricot 1992 Prognostic factors in myelodysplastic syndrome Leuk Res 16 109 15 10.1016/0145-2126(92)90109-K 1:STN:280:DyaK387it1OqtQ%3D%3D 1732663
6. K Nakai Y Kanda S Fukuhara H Sakamaki S Okamoto Y Kodera, et al. 2005 Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome Leukemia 19 396 401 10.1038/sj.leu.2403640 1:CAS:528:DC%2BD2MXhsFOqsrg%3D 15674354 (Pubitemid 40403316)
7. T De Witte 2000 Stem cell transplantation for patients with myelodysplastic syndrome and secondary leukemias Int J Hematol 72 151 6 11039662
8. CS Cutler SJ Lee P Greenberg HJ Deeg WS Perez C Anasetti, et al. 2004 A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndrome: delayed transplantation for low risk myelodysplasia is associated with improved outcome Blood 104 579 85 10.1182/blood-2004-01-0338 1:CAS:528:DC%2BD2cXlvFSmsL4%3D 15039286 (Pubitemid 38900045)
9. B Oran S Giralt R Saliba C Hosing U Popat I Khouri, et al. 2007 Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan Biol Blood Marrow Transplant 13 454 62 10.1016/j.bbmt.2006.11.024 1:CAS:528:DC%2BD2sXkslWitr4%3D 17382251 (Pubitemid 46421890)
10. L Lekakis M de Lima 2008 Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia Expert Rev Anticancer Ther 8 785 98 10.1586/14737140.8.5.785 18471050
11. C Denzlinger D Bowen D Benz K Gelly W Brugger L Kanz 2000 Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute leukaemia Br J Haematol 108 93 5 10.1046/j.1365-2141.2000.01825.x 1:CAS:528:DC%2BD3cXht1altb8%3D 10651730 (Pubitemid 30089939)
12. KB Miller K Kim FS Morrison JN Winter JM Bennett RS Neiman, et al. 1992 The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndrome Ann Hematol 65 162 8 10.1007/BF01703109 1:STN:280: DyaK3s%2Fkt1WrtQ%3D%3D 1420504
13. T Okamoto A Kanamaru C Shimazaki T Motoji Y Takemoto M Takahashi, et al. 2000 Combination chemotherapy with risk factor-adjusted dose attenuation for high-risk myelodysplastic syndrome and resulting leukemia in the multicenter study of the Japan Adult Leukemia Study Group (JALSG): results of an interim analysis Int J Hematol 72 200 5 1:CAS:528:DC%2BD3cXns1Cqsbo%3D 11039669
14. P Greenberg C Cox MM LeBeau C Fenaux P Morel G Sanz, et al. 1997 International scoring system for evaluating progenitors in myelodysplastic syndrome Blood 89 2079 88 1:CAS:528:DyaK2sXhvVars70%3D 9058730
15. K Yamada S Furusawa K Saito K Waga T Koike H Arimura, et al. 1995 Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study Leukemia 9 10 4 1:STN:280:DyaK2M7kslClug%3D%3D 7531259
16. AB Miller B Hoogstraten M Staquet A Winkler 1981 Reporting results of cancer treatment Cancer 47 207 14 10.1002/1097-0142(19810101)47:1<207::AID- CNCR2820470134>3.0.CO;2-6 1:STN:280:DyaL3M7htFOltw%3D%3D 7459811 (Pubitemid 11167383)
17. EP Alessandrino MG Della Porta A Bacigalupo MT Van Lint M Falda F Onida, et al. 2008 WHO classification and WPSS predict post-transplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) Blood 112 895 902 10.1182/blood-2008-03- 143735 1:CAS:528:DC%2BD1cXpsVaisLs%3D 18497321
18. K Nachtkamp A Kundgen C Strupp A Giagounidis G Kobbe N Gattermann, et al. 2009 Impact on survival of different treatments for myelodysplastic syndromes (MDS) Leuk Res 33 1024 8 10.1016/j.leukres.2008.12.019 1:CAS:528: DC%2BD1MXmtVWgurg%3D 19185917
19. J Ooi 2006 The efficacy of unrelated cord blood transplantation for adult myelodysplastic syndrome Leuk Lymphoma 47 599 602 10.1080/10428190500421013 16690517 (Pubitemid 43753369)
20. S Knipp B Hildebrand A Kundgen A Giagounidis G Kobbe R Haas, et al. 2007 Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes Cancer 110 345 51 10.1002/cncr.22779 1:CAS:528:DC%2BD2sXos1yrt70%3D 17559141 (Pubitemid 47121895)
21. P Fenaux GJ Mufti E Hellstrom-Lindberg V Santini C Finelli A Giagounidis, et al. 2009 Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomized, open-rabell, phase III study Lancet Oncol 10 223 32 10.1016/S1470-2045(09)70003-8 1:CAS:528:DC%2BD1MXisFWjsbc%3D 19230772